Featured
-
-
Article |
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma
- Dong-yang Ding
- , Xiao-jie Gan
- & Sheng-xian Yuan
-
Article
| Open AccessSpatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis
- Alphonse Charbel
- , Luca Tavernar
- & Benjamin Goeppert
-
Article
| Open AccessPrecision oncology for intrahepatic cholangiocarcinoma in clinical practice
- Aurelie Tomczak
- , Christoph Springfeld
- & Thomas Longerich
-
Article
| Open AccessGenomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
- Olaf Neumann
- , Timothy C. Burn
- & Daniel Kazdal
-
Article |
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer
- Mark K. Doherty
- , Vincent C. Tam
- & Jennifer J. Knox
-
Article |
Gallstones and risk of cancers of the liver, biliary tract and pancreas: a prospective study within two U.S. cohorts
- Xiao Luo
- , Wanshui Yang
- & Xuehong Zhang
-
Article
| Open AccessModelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells
- Guoying Zhou
- , Ruby Lieshout
- & Jaap Kwekkeboom
-
Article
| Open AccessHOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples
- Eleonora Loi
- , Cesare Zavattari
- & Patrizia Zavattari
-
Review Article |
Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy
- Roseanna C. Wheatley
- , Elaine Kilgour
- & Mairéad G. McNamara
-
Perspective
| Open AccessHighlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group
- Thibaud Koessler
- , Maria Alsina
- & Markus Moehler
-
Review Article |
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
- José J. G. Marin
- , Maria Giuseppina Prete
- & Chiara Braconi
-
Article
| Open AccessExogenous hormone use, reproductive factors and risk of intrahepatic cholangiocarcinoma among women: results from cohort studies in the Liver Cancer Pooling Project and the UK Biobank
- Jessica L. Petrick
- , Úna C. McMenamin
- & Katherine A. McGlynn
-
Article
| Open AccessEfficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial
- Ali Belkouz
- , Judith de Vos-Geelen
- & Heinz-Josef Klümpen
-
Article
| Open AccessEnhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study
- Jin Won Kim
- , Kyung-Hun Lee
- & Do-Youn Oh
-
Article
| Open AccessSOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance
- Xiaodong Yuan
- , Jun Li
- & Hong-Lei Weng
-
Article
| Open AccessDerazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- Vincenzo Mazzaferro
- , Bassel F. El-Rayes
- & Walid L. Shaib
-
Article
| Open AccessMismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma
- Benjamin Goeppert
- , Stephanie Roessler
- & Matthias Kloor
-
Article
| Open AccessA randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
- Yi Zheng
- , Xiaoxuan Tu
- & Weilin Wang
-
Article
| Open AccessCirculating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial
- Alison C. Backen
- , Andre Lopes
- & Juan W. Valle
-
Clinical Study
| Open AccessPhase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment
- Richard Kim
- , E Gabriela Chiorean
- & David Portnoy
-
Clinical Study
| Open AccessThe oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
- Rachna T Shroff
- , Mark Yarchoan
- & Nilofer S Azad
-
Clinical Study
| Open AccessA phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
- Johanna C Bendell
- , Milind Javle
- & Amita Patnaik
-
Clinical Study
| Open AccessEfficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
- Bum Jun Kim
- , Changhoon Yoo
- & Heung-Moon Chang
-
Clinical Study
| Open AccessValidation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder
- S D Kaupp-Roberts
- , G Yadegarfar
- & J K Ramage
-
Clinical Study
| Open AccessQuality of life, long-term survivors and long-term outcome from the ABC-02 study
- John Bridgewater
- , Andre Lopes
- & Harpreet Wasan
-
Clinical Study
| Open AccessCorrelations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy
- Toshikazu Moriwaki
- , Yoshiyuki Yamamoto
- & Ichinosuke Hyodo
-
Molecular Diagnostics
| Open AccessMajor histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer
- Benjamin Goeppert
- , Lena Frauenschuh
- & Wilko Weichert
-
Translational Therapeutics
| Open AccessNovel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer
- M Zuo
- , A Rashid
- & M Javle
-
Molecular Diagnostics
| Open AccessPrognostic significance of epithelial–mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray
- T Nitta
- , T Mitsuhashi
- & Y Matsuno
-
Clinical Study
| Open AccessConcurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy
- H Sasaki
- , Y Murakami
- & T Sueda
-
Clinical Study
| Open AccessPhase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
- A F Hezel
- , M S Noel
- & A X Zhu
-
Clinical Study
| Open AccessMultivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
- L Fornaro
- , S Cereda
- & G Brandi
-
Clinical Study
| Open AccessS0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
- A B El-Khoueiry
- , C Rankin
- & C D Blanke
-
Molecular Diagnostics
| Open AccessDirect targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis
- F Peng
- , J Jiang
- & R Qin
-
Molecular Diagnostics
| Open AccessPrognostic impact of tumour-infiltrating immune cells on biliary tract cancer
- B Goeppert
- , L Frauenschuh
- & W Weichert
-
Clinical Study
| Open AccessA phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
- J K Lee
- , M Capanu
- & G K Abou-Alfa
-
Epidemiology
| Open AccessGallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma
- H Nordenstedt
- , F Mattsson
- & J Lagergren
-
Molecular Diagnostics
| Open AccessE/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma
- K Araki
- , T Shimura
- & H Kuwano
-
Molecular Diagnostics
| Open AccessA combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures
- N S Sandanayake
- , J Sinclair
- & S P Pereira
-
Epidemiology
| Open AccessMetabolic syndrome and insulin resistance in relation to biliary tract cancer and stone risks: a population-based study in Shanghai, China
- F M Shebl
- , G Andreotti
- & A W Hsing
-
Molecular Diagnostics
| Open AccessPrognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
- M Miyamoto
- , H Ojima
- & T Shibata
-
Molecular Diagnostics
| Open AccessCpG-island methylation study of liver fluke-related cholangiocarcinoma
- R Sriraksa
- , C Zeller
- & T Limpaiboon
-
Clinical Study
| Open AccessPhase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
- K-p Kim
- , G Jang
- & T W Kim
-
Clinical Study
| Open AccessDevelopment of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21
- E Friend
- , G Yadegarfar
- & J K Ramage
-
Clinical Study
| Open AccessGemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- T Okusaka
- , K Nakachi
- & Y Nimura
-
Short Communication
| Open AccessDiabetes in relation to biliary tract cancer and stones: a population-based study in Shanghai, China
- F M Shebl
- , G Andreotti
- & A W Hsing
-
Short Communication
| Open AccessReproductive factors and risks of biliary tract cancers and stones: a population-based study in Shanghai, China
- G Andreotti
- , L Hou
- & A W Hsing